Datasets:
Inabia-AI
/
continued-pretraining

Dataset card Data Studio Files
xet
 Community
1
text
stringlengths
1
5.46k
7.10. Interest on Late Payments..................................................................................... 54
7.11. Financial Records.................................................................................................. 54
7.12. Audit ..................................................................................................................... 54
7.13. Right to Offset....................................................................................................... 55
7.14. Diagnostic and Veterinary Products ..................................................................... 55
7.15. No Other Compensation ....................................................................................... 55
7.16. No Limitation........................................................................................................ 55
7.17. Financial Obligations Under WuXi Agreements.................................................. 55
ARTICLE 8 INTELLECTUAL PROPERTY .............................................................................. 55
8.1. Ownership of Intellectual Property....................................................................... 55
8.2. Prosecution and Maintenance of Patents .............................................................. 57
8.3. Enforcement of Patents ......................................................................................... 62
8.4. Infringement Claims by Third Parties................................................................... 67
8.5. Invalidity or Unenforceability Defenses or Actions ............................................. 68
8.6. Third Party Licenses and Patents.......................................................................... 71
8.7. Product Trademarks .............................................................................................. 72
8.8. Inventor's Remuneration ...................................................................................... 73
ARTICLE 9 CONFIDENTIALITY AND NON-DISCLOSURE ................................................ 74
9.1. Confidentiality Obligations................................................................................... 74
9.2. Permitted Disclosures ........................................................................................... 75
9.3. Additional Permitted Disclosures and Use by AbbVie......................................... 76
9.4. Additional Permitted Disclosures and Use by Cugene ......................................... 76
9.5. Use of Name ......................................................................................................... 77
9.6. Public Announcements ......................................................................................... 77
9.7. Publications........................................................................................................... 78
9.8. Return of Confidential Information ...................................................................... 79
ARTICLE 10 REPRESENTATIONS AND WARRANTIES...................................................... 79
10.1. Mutual Representations and Warranties ............................................................... 79
10.2. Additional Representations, Warranties and Covenants of Cugene ..................... 79
10.3. Additional Covenants of Cugene .......................................................................... 85
10.4. Additional Representations, Warranties and Covenants of AbbVie..................... 87
10.5. DISCLAIMER OF WARRANTIES..................................................................... 88
10.6. Anti-Bribery and Anti-Corruption Compliance.................................................... 88
ARTICLE 11 INDEMNITY......................................................................................................... 88
11.1. Indemnification of Cugene ................................................................................... 88
11.2. Indemnification of AbbVie ................................................................................... 89
11.3. Indemnification Procedures .................................................................................. 89
11.4. Special, Indirect and Other Losses........................................................................ 92
11.5. Insurance ............................................................................................................... 92
ARTICLE 12 TERM AND TERMINATION .............................................................................. 93
12.1. Term and Expiration ............................................................................................. 93
12.2. Termination........................................................................................................... 93
12.3. Rights in Bankruptcy ............................................................................................ 95
12.4. Consequences of Termination............................................................................... 96
12.5. Transition Agreement. .......................................................................................... 99
12.6. Reverse Royalty .................................................................................................. 102
12.7. AbbVie Rights in Lieu of Termination............................................................... 102
12.8. Remedies............................................................................................................. 103
12.9. Accrued Rights; Surviving Obligations .............................................................. 103
ARTICLE 13 MISCELLANEOUS ............................................................................................ 104
13.1. Force Majeure ..................................................................................................... 104
13.2. Export Control .................................................................................................... 104
13.3. Assignment ......................................................................................................... 104
13.4. Severability ......................................................................................................... 106
13.5. Dispute Resolution.............................................................................................. 106
13.6. Governing Law ................................................................................................... 107
13.7. Notices ................................................................................................................ 107
13.8. Entire Agreement; Amendments......................................................................... 108
13.9. English Language................................................................................................ 108
13.10. Equitable Relief .................................................................................................. 108
13.11. Waiver and Non-Exclusion of Remedies............................................................ 109
13.12. No Benefit to Third Parties ................................................................................. 109
13.13. Further Assurance ............................................................................................... 109
13.14. Relationship of the Parties .................................................................................. 109
13.15. References........................................................................................................... 110
13.16. Construction........................................................................................................ 110
13.17. Performance by Affiliates ................................................................................... 110
13.18. Change in Control of Cugene ............................................................................. 110
13.19. Counterparts........................................................................................................ 111
Schedules
Schedule 1.54 Corporate Names
Schedule 1.94 Existing Patents Schedule
Schedule 1.116 In-License Schedule
Schedule 1.123 Indications
Schedule 1.126 Initial Development Plan and Budget
Schedule 2.3.4 Permitted Entities
Schedule 7.5 Sample Royalty Calculation
Schedule 9.6 Form of Joint Press Release
Schedule 10.2.1(c) Cugene Patents
Schedule 13.5.3 ADR Procedures
COLLABORATION AND LICENSE OPTION AGREEMENT
This Collaboration and License Option Agreement (this "Agreement") is made and entered into as of May 6, 2022 (the "Effective Date") by and between Cugene, Inc., a Delaware corporation ("Cugene"), and AbbVie Global Enterprises Ltd., a Bermudian limited company ("AbbVie"). Cugene and AbbVie are sometimes referred to her...
RECITALS
WHEREAS, Cugene owns and controls certain intellectual property rights with respect to certain IL-2 (as defined below) muteins in the Territory (as defined below); and
WHEREAS, the Parties wish for Cugene to perform certain Development (as defined below) activities with respect to such muteins; and
WHEREAS, Cugene wishes to grant to AbbVie, and AbbVie wishes to obtain, an option to take an exclusive license under such intellectual property rights to Exploit (as defined below) Licensed Therapeutics (as defined below) and Licensed Products (as defined below) in the Field (as defined below) in the Territory, in acco...
NOW, THEREFORE, in consideration of the premises and the mutual promises and conditions set forth herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows:
ARTICLE 1 DEFINITIONS
Unless otherwise specifically provided herein, the following terms shall have the following meanings:
1.1. "418 Patent" means any Cugene Patent related to the Excluded Compound, including WO/2020/252418.
1.2. "AbbVie" has the meaning set forth in the preamble hereto.
1.3. "AbbVie Grantback Agreement Know-How" means all Information Controlled by AbbVie or its Affiliates during the Term or as of the effective date of the applicable termination of this Agreement that was conceived, discovered, developed or otherwise made by or on behalf of AbbVie (or its Affiliates or its or their Sub...
1.4. "AbbVie Grantback Agreement Patent" means any Patent Controlled by AbbVie or its Affiliates during the Term or as of the effective date of the applicable termination of this Agreement that was conceived, discovered, developed or otherwise made by or on behalf of AbbVie (or its Affiliates or its or their Sublicense...
1.5. "AbbVie Grantback Background Know-How" means all Information Controlled by AbbVie or its Affiliates as of the effective date of the applicable termination of this Agreement, other than AbbVie Grantback Agreement Know-How, that is not generally known and is necessary for the Exploitation of any Reversion Product as...
1.6. "AbbVie Grantback Background Patent" means any Patent Controlled by AbbVie or its Affiliates as of the effective date of the applicable termination of this Agreement, other than AbbVie Grantback Agreement Patents, that is necessary for the Exploitation of any Reversion Product as of such effective date of terminat...
1.7. "AbbVie Grantback Know-How" means the AbbVie Grantback Agreement Know-How and AbbVie Grantback Background Know-How.
1.8. "AbbVie Grantback Patents" means the AbbVie Grantback Agreement Patents and AbbVie Grantback Background Patents.
1.9. "AbbVie Indemnitees" has the meaning set forth in Section 11.2.
1.10. "AbbVie Liquid Formulation" means any formulation Developed by or on behalf of AbbVie during the Term specifically for a Licensed Product that is liquid above 0°C. For clarity, AbbVie Liquid Formulation does not include the liquid formulation for the Licensed Product described in the Initial Development Plan and ...
1.11. "AbbVie Patents" means all Patents owned or Controlled, that are conceived, discovered, developed or otherwise made, by or on behalf of AbbVie under this Agreement (other than the Joint Patents). For clarity, AbbVie Patents shall not include Cugene Patents.